VISTARIL (hydroxyzine pamoate) by Pfizer is clinical pharmacology hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Approved for anxiety. First approved in 1959.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
VISTARIL (hydroxyzine pamoate) is an oral anxiolytic suspension approved in 1959 for the treatment of anxiety. It works by suppressing activity in key subcortical CNS regions and exhibits muscle relaxant, antihistaminic, analgesic, and antiemetic properties. Clinical effects are typically noted within 15–30 minutes of oral administration.
Product is in late-stage lifecycle with modest Part D uptake; commercial teams should focus on generic mitigation and transition planning as LOE approaches.
CLINICAL PHARMACOLOGY Hydroxyzine pamoate is unrelated chemically to the phenothiazines, reserpine, meprobamate, or the benzodiazepines. Hydroxyzine pamoate is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the…
Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry
Worked on VISTARIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on VISTARIL offers exposure to a legacy small-molecule franchise with stable, predictable commercial operations but limited growth upside. Career trajectory depends on readiness for LOE transition work, including generic competition mitigation and potential portfolio rationalization.